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Objective: To report the clinical characteristics, pathologic findings and treatments of a patient with a Caesarean
scar choriocarcinoma.
Patient history: A 22-year-old woman had a diagnosis of primary gestational choriocarcinoma in a uterine Caesarean
scar misdiagnosed as a normal Caesarean scar pregnancy. The patient underwent selective uterine artery embolization
coupled with methotrexate arterial injection, along with dilatation and curettage of the uterine Caesarean scar. Finally,
she received eight courses of multiagent chemotherapy. The reproductive function of the patient was preserved.
Conclusions: Primary gestational choriocarcinoma out of the uterine corpus is a rare disease. A Caesarean scar
choriocarcinoma is an extremely unusual example of this entity because of its unique position. To the best of our
knowledge, this is the first report of this phenomenon. Our experience and a literature review suggest that a clinical
diagnosis of a primary gestational choriocarcinoma of the uterine Caesarean scar is difficult to make, and uterine artery
embolization is beneficial to prevent massive bleeding before curettage.
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Gestational trophoblastic disease (GTD) includes the
tumour spectrum of hydatidiform mole (complete and
partial), invasive mole, choriocarcinoma and placental-site
trophoblastic tumour. Gestational choriocarcinoma usually
arises in the uterine body. It is a highly chemosensitive
tumour type and has a very good prognosis, even in
advanced stages. An accurate and prompt diagnosis is
crucial. Extrauterine choriocarcinoma is a rare entity. Only
a few cases have been reported in the literature up to now,
and most of these cases were located in the uterine cervix
[1-4]. Other extrauterine locations have also been reported,
including the ovary [5,6], Fallopian tube [7], vagina [8],
vulva [9] and gut [10]. Choriocarcinoma in a Caesarean
scar has not been reported before. Here, we present our
experience with the diagnosis and management of a rare
case of a Caesarean scar choriocarcinoma.* Correspondence: fbzhuxiaoming@163.com
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On 6 July 2011, a 22-year-old woman (gravida 4, para 2)
was admitted to our hospital with a complaint of amenor-
rhea for 47 days and irregular vaginal bleeding for half a
month. She had had her first pregnancy three years previ-
ously, which ended with a full-term vaginal delivery. Her
second normal pregnancy ended in an induced abortion in
the first trimester two years previously. Her third preg-
nancy ended in a full-term delivery by Caesarean section in
July 2010. She had an inevitable abortion ending in curet-
tage four months previously. Her menstrual cycle was regu-
lar (30 days) with seven days duration. Her most recent
menstrual period was on 19 May 2011. Bimanual examin-
ation revealed a mildly enlarged uterine corpus with an
obviously enlarged uterine isthmus and a closed cervical
os. A transvaginal sonogram showed a 6.6 × 5.6 × 5.5 cm
mass implanted in the anterior wall of the uterine isthmus
embedded in and surrounded by myometrium and sepa-
rated from the endometrial cavity. The lesion was bulging
toward the serosa with a thin layer of overlying myome-
trium (Figure 1A). Both the uterine cavity and the cervical
canal were empty. Pulsed Doppler ultrasonography
showed abundant blood flow signals and a low resistive
index (RI = 0.38) around the lesion. The results ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Transvaginal ultrasonography of the patient before (A) and after (B) dilation and curettage (D&C). The uterine cavity and
cervical canal were empty. A mass implanted in the anterior wall of the uterine Caesarean scar (indicated by the arrow) embedded and
surrounded by thin myometrium and separated from the endometrial cavity was visible on the retroverted uterus. Ultrasonography revealed that
the mass was heterogeneous with a mixture of cystic and solid echogenicity. (A) Two days before D&C (longitudinal section). The size of the
mass was 6.6 × 5.6 × 5.5 cm. RI = 0.38. (B) Five days after D&C (longitudinal section). The size of the mass was 4.7 × 5.7 × 4.5 cm. Abundant blood
flow signals and low RI around the mass, RI = 0.29.
Qian and Zhu European Journal of Medical Research 2014, 19:25 Page 2 of 5
http://www.eurjmedres.com/content/19/1/25computed tomography (CT) of the chest and brain were
normal. There were no pathologic findings in the upper
abdominal ultrasound. The blood level of β-human chori-
onic gonadotropin (β-HCG) was 312,468 IU/l (normal
value, <5.3 IU/l) on 6 July 2011.
Because Caesarean scar choriocarcinoma is rare, its clin-
ical diagnosis is very hard to make in a patient without me-
tastasis before a pathological examination. Furthermore,
we had no experience of the clinical characteristics and
diagnosis of Caesarean scar choriocarcinoma. The patient
was diagnosed as having a normal Caesarean scar preg-
nancy (CSP). After written informed consent was obtained,
she was treated with a selective uterine artery embolization
(UAE) coupled with an arterial injection of 70 mg of
methotrexate (MTX) after a routine clinical and laboratory
evaluation on 7 July 2011. The patient underwent careful
dilation and curettage (D&C) under transabdominal ultra-
sound guidance the next day. Bleeding was initially brisk
but decreased substantially by the time most adherent tis-
sue had been removed. The curettage specimen consisted
of approximately 4.0 × 4.0 × 3.0 cm of necrotic tissue mixed
with blood clots. An unusually large anterior uterine wall
defect was found on the ultrasonic scan during the oper-
ation. The total blood loss was 200 ml and iodoform gauze
packing was left in situ for 24 hours to decrease the risk of
heavy vaginal bleeding. The patient’s hemodynamic status
remained stable during and after the procedure. The post-
operative recovery was uneventful, and the patient’s serum
β-HCG levels declined from 189,930 IU/l to 110,984 IU/l
the day after the operation.
However, transvaginal ultrasonography revealed a 4.7 ×
5.7 × 4.5 cm complex mass protruding into the bladder
and increased vascularity at the anterior lower uterine wall
(RI = 0.29) five days after the D&C (Figure 1B). A histo-
logical examination confirmed the diagnosis of choriocar-
cinoma. Histology revealed a proliferation of trophoblasticand syncytiotrophoblastic cells with clearly malignant fea-
tures in the clot, and chorionic villi were not identified
(Figure 2A). Immunohistochemical staining for β-HCG
was strongly positive (Figure 2B), and the Ki-67 index
was high in the tumour tissue (Figure 2C). Human pla-
cental lactogen was weakly positive in the tumour tissue
(Figure 2D). The diagnosis of a Caesarean scar choriocar-
cinoma was confirmed on the basis of all the findings. The
patient was accepted as International Federation of Gyne
cology and Obstetrics stage I:8 and received eight courses
of multiagent chemotherapy (etoposide, actinomycin D,
methotrexate, cyclophosphamide and vincristine, EMA/
CO). Her progress was monitored with serial weekly blood
β-HCG measurements. The β-HCG levels declined from
18,121 IU/l before the first course of EMA/CO therapy to
3.57 IU/l after four cycles of EMA/CO therapy on 8
September 2011. The post-chemotherapy period was
excellent, without any major complications.
Discussion
Gestational choriocarcinoma may accompany or follow
any type of pregnancy, such as a hydatidiform mole, a
normal term pregnancy, an abortion or an ectopic preg-
nancy. A CSP is defined as an ectopic pregnancy embed-
ded in the myometrium of a previous Caesarean scar,
which is a late serious complication of a Caesarean
section. The incidence of CSP is 1:2,216 and its rate is
6.1% in women with an ectopic pregnancy and at least
one previous Caesarean section [11]. The incidence of
CSP is extremely low. However, it has been increasing
with the recently increasing numbers of Caesarean sec-
tions. Early diagnosis and early treatment remain the key
for the successful treatment of CSP. Colour Doppler
ultrasound is important in its early diagnosis and treat-
ment. Different therapeutic modalities may be selected
according to specific patient conditions [12].
Figure 2 Histologic section of Caesarean scar choriocarcinoma. (A) Marked nuclear and cellular atypia and increased mitotic activity (H&E,
×400). (B) Immunohistochemical staining of tumour cells was positive for β-HCG (immunohistochemistry, ×400). (C) Ki-67 positive tumour cells
(immunohistochemistry, ×200). (D) Human placental lactogen positive tumour cells (immunohistochemistry, ×200).
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October 2013 using the keywords ‘Caesarean scar’, ‘chorio-
carcinoma’, ‘molar’ and ‘hydatidiform’ to look for reports
of Caesarean scar GTD. We could not find any published
cases of Caesarean scar choriocarcinoma. So far, three
cases of Caesarean scar molar pregnancies have been
reported in the literature [13-15], and as with the rare
choriocarcinoma in a Caesarean scar, they presumably
carry a high risk of uterine rupture and uncontrollable
haemorrhage. A prompt and accurate diagnosis is crucial.
However, primary gestational choriocarcinoma out of the
uterine cavity is a very rare disease. Caesarean scar chorio-
carcinoma is an extremely unusual example of this entity
because of its unique position. Awareness of the possibility
of lesions in a previous Caesarean scar is needed to avoid
potentially catastrophic complications.
In this report, the patient’s serum β-HCG level (312,
468 IU/l) was much higher than in a normal pregnancy
(50,000 to 100,000 IU/l). Furthermore, the patient com-
plained of amenorrhea for 47 days and had an obvious,
enlarged uterine isthmus mass (6.6 × 5.6 × 5.5 cm) and
abundant blood flow. A high degree of suspicion is essen-
tial for an early diagnosis of Caesarean scar GTD. Unfortu-
nately, this case was not correctly diagnosed before
treatment. Caesarean scar choriocarcinoma should beincluded in the differential diagnosis of cervical lesions in
patients in their reproductive years. It is easily misdiag-
nosed as a uterine cervical pregnancy, a threatened abor-
tion, a normal CSP, a cervical polyp or another cervix
neoplasm. The clinical diagnosis of primary gestational
choriocarcinoma in a Caesarean scar is very difficult to
make before a pathological examination. Wu et al. [13]
reported a case of a partial molar pregnancy in a Caesarean
scar that had been misdiagnosed as a threatened abortion
at a local medical clinic in 2006. Michener et al. [14]
reported a second case of a Caesarean scar molar preg-
nancy, and the diagnosis was delayed until 10 months later
when the patient presented with vaginal haemorrhage,
which required an emergency hysterectomy. The histo-
logical examination confirmed molar tissue in the hysterec-
tomy specimen. Abnormal elevated serum β-HCG levels
coupled with CT scans of the chest and brain are helpful to
establish a diagnosis. When ultrasound findings indicate a
suspected CSP, abnormally elevated serum β-HCG levels
could increase the suspicion of a GTD in the Caesarean
scar, especially choriocarcinoma. Clinicians should be
aware of this diagnosis in spite of a lack of metastasis.
A suction evacuation under ultrasound guidance was
needed to obtain tissue for histological diagnosis. In our
case, the patient had a blood loss of 200 ml during the
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UAE to reduce the risk of haemorrhage. Ko et al. [15]
reported a case of a Caesarean scar molar pregnancy diag-
nosed before treatment. Active bleeding was present at
the end of the D&C, and a UAE was performed to control
the bleeding immediately. However, the total blood loss
was 1,000 ml. Therefore, should UAE be offered to all pa-
tients with Caesarean scar GTD before suction curettage?
Uterine artery embolization is a minimally invasive non-
surgical treatment widely used to control haemorrhage
and preserve the uterus and the patient’s future fertility. It
is an alternative to treatments for CSP, and it has been
shown to have a high success rate and a low complication
rate. Followed by uterine curettage, UAE might be an
effective and safe treatment for CSP [16]. Superselective
embolization of both uterine arteries was performed using
gelatin sponge powder by two experienced radiologists.
The Seldinger technique was applied to puncture and
catheterize the bilateral internal iliac arteries via the right
femoral artery, and the procedure was performed under
local anaesthesia. Postembolization angiography was per-
formed to confirm that the occlusion of the vessels was
complete. Uterine artery embolization is a priority alterna-
tive for the D&C of GTD within Caesarean scars for
several reasons. Serious complications related to UAE
have been reported [17]. This includes labial or vaginal
necrosis with bladder fistula, endometrial atrophy or per-
manent amenorrhea. There is no clear consensus on the
optimal management of CSP; UAE followed by suction
curettage appears to have more of an advantage and might
be a priority option. Uterine artery embolization prevents
massive bleeding and preserves the uterus, so we recom-
mend UAE as a priority alternative for the D&C of GTD
within Caesarean scars for several reasons. First, patients
with this pathology are at a high risk of severe, potentially
life-threatening bleeding, which may lead to a hysterec-
tomy, with dramatic consequences for their reproductive
future. The purpose of UAE is to block the blood flow in
the designated uterine artery to decrease vascularization
at the site of the lesion. Second, UAE can reduce the
occurrence of patients with an unstable hemodynamic sta-
tus owing to heavy bleeding. Finally, UAE makes the D&C
procedure safer and more proactive.
This case was treated with preventive UAE coupled with
a MTX arterial injection before the D&C. Methotrexate is
an agonist of folinic acid implicated in DNA synthesis. A
combined MTX regimen, which may be systemic or local,
single dose or multidose, can interrupt CSPs. Pascual
et al. [18] reported that a patient with CSP had been
treated conservatively and successfully with a local injec-
tion of MTX into the gestational sac under transvaginal
ultrasonographic guidance.
Wang et al. [19] reported that 15 out of 128 CSP pa-
tients still had massive bleeding (blood loss of 500 ml ormore) during D&C after UAE. They found that a gesta-
tional age of eight weeks or more, a CSP mass diameter of
6 cm or more, and a thinner myometrium at the implant-
ation site were risk factors for massive bleeding during
surgery after a preventive UAE. This patient had a large
amount of gestational tissue in the Caesarean scar and a
thinner myometrium at the implantation site. However,
the intraoperative blood loss was 200 ml in this case. This
might be because the main purpose of the D&C was to
obtain tissue for a histological diagnosis. Ultrasonography
revealed there was still a 4.7 × 5.7 × 4.5 cm mass at the
anterior lower uterine wall five days after the D&C. This
patient might have had massive bleeding if we had tried to
remove the mass completely. To prevent massive bleed-
ing, we suggest that residual gestational tissue might not
be removed completely when tissue is closely attached to
the uterus, even after a preventive UAE.
Conclusions
In conclusion, owing to the increasing incidence of CSP,
doctors may encounter more cases of Caesarean scar
GTD. Because Caesarean scar choriocarcinoma is rare, no
therapeutic protocols have been established. There may be
different treatment options for different patients. We be-
lieve that the treatment selection should be based on the
characteristics of the patient, combining the therapies of
choriocarcinoma with CSP. The conservation of repro-
ductive function should be considered if possible, and pre-
ventive UAE is beneficial to prevent massive haemorrhage
before careful D&C. However, further studies are needed
to reach a more definitive conclusion.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the editor in chief of this journal.
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